Min and colleagues corroborated this evidence using the Methylight assay to evaluate a panel of five methylation markers (i.e., Calcium Voltage-Gated Channel Subunit Alpha1 G, Insulin Like Growth Factor 2, Neurogenin 1, Runt-Related Transcription Factor 3, and Suppressor Of Cytokine Signaling 1 genes; CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1, respectively) in CRC patients [49]. This evidence concerns the gene RUNX3 and colorectal carcinoma.